PrediabetesPhase 2/3NCT07815236
Diabetes Prevention Through Genetics, Familial History and Behavior Change
A Phase 2/3 study testing LEGACY DPP and DPP in people with Prediabetes and Weight Loss, run by Morehouse School of Medicine.
Trial summary
The goal of this clinical trial is to learn if adding a family engagement component to the standard Diabetes Prevention Program (DPP) improves outcomes for adults with prediabetes. It will also learn about the effects of this approach on family members' health. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Prediabetes, Weight Loss
- What is being tested?
- LEGACY DPP and DPP
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2027to 31 Jan 2031
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥18 years.
- Fasting HbA1c 5.7-6.4% confirmed by CLIA-waived point-of-care testing.
- Body Mass Index ≥25 kg/m².
- Able to provide informed consent.
- Has an adult household/family or framily (fictive kin) member willing to enroll as a paired participant.
- Willing to attend in-person sessions
Who cannot join
- Minors <18 years
- Prior diagnosis of Type 1 or Type 2 Diabetes.
- HbA1c ≥6.5% at screening (Aim 1/2 curriculum eligibility)
- Current glucose-lowering medication use
- Pregnancy
- Physical-activity contraindications
- Individuals unable to speak or understand English
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Legacy-DPP: Diabetes Prevention Through Genetics, Familial History and Behavior Change A Family-Enhanced, Genetically-Informed Diabetes Prevention Program
The goal of this clinical trial is to learn if adding a family engagement component to the standard Diabetes Prevention Program (DPP) improves outcomes for adults with prediabetes. It will also learn about the effects of this approach on family members' health.
The main questions it aims to answer are:
Read more
- Does adding family health history collection and family participation to the DPP improve session attendance compared to standard DPP?
- Does this family-centered approach lead to greater weight loss and HbA1c (blood sugar) reduction compared to standard DPP?
- Do health improvements extend to participants' family members, and what factors explain differences in family-level outcomes?
Researchers will compare an adapted DPP with a family component to the standard DPP (individual-focused) to see if involving family members improves diabetes prevention outcomes.
Participants will:
- Be assigned to one of two groups: adapted DPP with family sessions, or standard DPP
- If assigned to the adapted DPP, complete a family health history using the Center for Disease Control and Prevention's (CDC) My Family Health Portrait tool and attend 6 additional sessions with family members focused on personalized risk communication
- Attend regular checkups to measure weight and HbA1c at 6 and 12 months
- Have session attendance tracked throughout the program
- Family members of participants may also be asked to complete health assessments to measure any changes in their own health behaviors
Read the detailed description
Type 2 diabetes affects 38.4 million U.S. adults, and an additional 97.6 million adults have prediabetes and are at risk of developing the disease. This burden falls disproportionately on racial and ethnic minority families and rural communities.
This clinical trial aims to determine whether embedding family engagement and family health history into the Diabetes Prevention Program (DPP) improves adherence, weight loss, and glycemic outcomes among adults with prediabetes, compared to the standard individual-focused DPP.
Participants will be 200 index participants with prediabetes, along with their family members, recruited from rural and urban sites and stratified by geographic location. Index participants will be block randomized to receive either standard DPP or an adapted version that adds 6 weeks of family health history and genetics education-using the CDC's My Family Health Portrait tool-paired with family participation and skill-building sessions.
All participants will attend regular clinic visits to monitor weight and HbA1c at 6 and 12 months and will have session attendance tracked throughout. Family members will also complete health assessments to measure whether health improvements extend beyond the index participant, and researchers will use the Actor-Partner Interdependence Model to identify factors explaining variation in family-level outcomes.
This is a 2-arm randomized controlled trial comparing standard DPP to a family-adapted DPP incorporating family health history, genetics education, and family skill-building.
- Conditions
- Prediabetes, Weight Loss
- Being tested
- LEGACY DPP, DPP
- Keywords
- Prediabetic State, Diabetes Mellitus, Type 2, Prevention and Control, Family Health, Health Status Disparities, Rural Health
- Medical subject headings
- Prediabetic State, Weight Loss, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LEGACY DPPBehavioural
The index partner will participate in an adapted DPP as a dyad with a family member with family health history and family participation and skill building
Participants will receive
- family health history sessions
- core behavioral weight loss group sessions
- a family skill building segment covering cohesion and communication during core sessions
DPPBehavioural
The index partner will participate in standard DPP
Participants will receive
- core behavioral weight loss group sessions
| Study group | Role | What they receive |
|---|---|---|
| Lifestyle Engagement through Genetics and Collaborative familY DPP (LEGACY DPP) | Experimental | Participants will receive the LEGACY DPP intervention Receives: Behavioral: LEGACY DPP |
| Diabetes Prevention Program (DPP) | Active comparator | Participants will receive the DPP intervention Receives: Behavioral: DPP |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Percent change in body weight
Body weight (kg) expressed as a continuous variable will be collected on a digital scale.
Measured: Baseline, 6 months, 12 months
Secondary outcomes (15)
Mean Change in Blood Pressure ( Systolic and diastolic)
Blood Pressure ( Systolic and diastolic) measured after 5 minutes of rest and taken in the same position throughout the study.
Measured: Baseline, 6 months, 12 months
Mean Change in glycosloated hemoglobin(HbA1c)(fasting, CLIA-waived assay)
Blood (~20 mL) will be collected to assess changes in glycosloated hemoglobin
Measured: Baseline, 6 months, 12 months
Mean Change in Fasting lipid panel (total cholesterol, High Denisity Lipids(HDL), Low density lipids (LDL), triglycerides)
Fasting lipid panel will measured to assess changes in total cholesterol, HDL, LDL, and triglycerides.
Measured: Baseline, 6 months, 12 months
Mean Change in Skin carotenoids
Skin carotenoids will be assessed using a VeggieMeter as an indicator for fruit and vegetable intake.
Measured: Baseline, 6 months, 12 months
Mean Change in Physical activity steps
Steps will be measured using an activity tracker e.g., Fitbit
Measured: Baseline, 6 months, 12 months
Mean Change in Self-Regulation of Eating Behaviors
The Eating Behavior Inventory (20 items) measures the adoption of eating behaviors associated with weight loss (e.g., monitoring quantity eaten, frequency of weighing, shopping from a list) to measure self-regulation behaviors. Items are rated on a 5-point frequency scale from "never or hardly ever" to "always or almost always." Scores range from 26 to 130
Measured: Baseline, 6 months, 12 months
Mean Change in Self-Efficacy of Eating Behaviors
Measured by survey responses to the Weight Efficacy Lifestyle Questionnaire Short Form (WEL-SF).Scale goes from 0 (not at all confident) to 10 (very confident). Higher scores mean better self efficacy.
Measured: Baseline, 6 months, 12 months
Mean Change in Self-Efficacy of Physical Activity
The confidence subscale of the Patient-centered Assessment and Counseling for Exercise Adult Diet and Physical Activity Measure (6 items; ) measures confidence in participating in regular exercise or physical activity in different situations (e.g., "How confident are you that you would participate in regular exercise or physical activity: When I am tired?"). Items rated on a scale from 1 ("not at all confident") to 6 ("extremely confident"). Higher scores show higher self-efficacy.
Measured: Baseline, 6 months, 12 months
Mean Change in Social Support for Eating
The Social Support and Eating Habits Survey (10 items) measures social support specific to healthy eating. Subscales assess encouragement for eating behaviors from partners (e.g., "Encouraged me not to eat 'unhealthy food' when I am tempted") and discouragement for eating behaviors from partners (e.g., "Brought home foods I am trying not to eat"). The items are rated on a scale of "none" to "very often." Total scores range from 5 to 50, with higher scores indicating more social support for eating behaviors.
Measured: Baseline, 6 months, 12 months
Mean Change in Social Support for Exercise
The exercise participation subscale of the Social Support and Exercise Survey (10 items) measures social support specific to exercise behaviors. The subscale assesses the level of support for exercise from partners. Subscale example items include "Exercised with me" and "Criticized or made fun of me for exercising." Total scores range from 5 to 50, with higher scores indicating more social support for exercise participation behaviors.
Measured: Baseline, 6 months, 12 months
Mean Change in Family Communication
Family communication is assessed with the communication subscale of the McMaster Family Assessment Device (6 items). Communication is defined as the exchange of information among family members. Items focused on whether verbal messages were clear and direct for the intended recipient. Responses ranged from "strongly agree" to "strongly disagree." Higher scores represent unhealthy communication.
Measured: Baseline, 6 months, 12 months
Mean Change in Family Cohesion
The cohesion subscale (10 items) of the Family Adaptability and Cohesion Evaluation Scale III measures the emotional bonding family members have with one another. Items like "Family members ask each other for help" rated on a 5-point Likert scale from "almost never" to "almost always."
Measured: Baseline, 6 months, 12 months
Mean Change in Family Emotional Involvement
The family emotional involvement (7 items) of the Family Emotional Involvement and Criticism Scale rate items on a 5-point Likert scale, as above.
Measured: Baseline, 6 months, 12 months
Mean Change in Family Perceived Criticism
The perceived criticism (7 items) subscales of the Family Emotional Involvement and Criticism Scale rate items like on a 5-point Likert scale, as above.
Measured: Baseline, 6 months, 12 months
Mean Change in Family Collaborative problem solving
The Family Problem-Solving Communication Index (10 items) was used to measure the specific communication style that families use to manage and solve problems and conflicts in various types of stressful situations. Consisting of 2 subscales, affirmatory communication and incendiary communication, the response options were "false," "mostly false," "mostly true," and "true."
Measured: Baseline, 6 months, 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study start1 Jan 2027 (estimated)
- Primary completion31 Jan 2031 (estimated)
- Study completion31 Jan 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PrediabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Morehouse School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Candice Alick, PhD, Morehouse School of Medicine
- Investigators
- Candice L Alick, PhD, Principal investigator, Morehouse School of MedicineTennille Leak-Johnson, PhD, Principal investigator, Morehouse School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07815236
- Sponsor's protocol ID
- 1R01MD021606
- Status last verified
- Oct 2026
- First submitted
- 6 Sep 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Legacy-DPP: Diabetes Prevention Through Genetics, Familial History and Behavior Change A Family-Enhanced, Genetically-Informed Diabetes Prevention Program
- ClinicalTrials.gov ID
- NCT07815236
- Acronym / sponsor ID
- 1R01MD021606
- Conditions
- Prediabetes, Weight Loss
- Keywords
- Prediabetic State, Diabetes Mellitus, Type 2, Prevention and Control, Family Health, Health Status Disparities, Rural Health
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Morehouse School of MedicineUniversity, hospital or other
- Study start
- 1 Jan 2027 (estimated)
- Primary completion
- 31 Jan 2031 (estimated)
- Study completion
- 31 Jan 2031 (estimated)
- First posted
- 11 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if adding a family engagement component to the standard Diabetes Prevention Program (DPP) improves outcomes for adults with prediabetes. It will also learn about the effects of this approach on family members' health.
The main questions it aims to answer are:
- Does adding family health history collection and family participation to the DPP improve session attendance compared to standard DPP?
- Does this family-centered approach lead to greater weight loss and HbA1c (blood sugar) reduction compared to standard DPP?
- Do health improvements extend to participants' family members, and what factors explain differences in family-level outcomes?
Researchers will compare an adapted DPP with a family component to the standard DPP (individual-focused) to see if involving family members improves diabetes prevention outcomes.
Participants will:
- Be assigned to one of two groups: adapted DPP with family sessions, or standard DPP
- If assigned to the adapted DPP, complete a family health history using the Center for Disease Control and Prevention's (CDC) My Family Health Portrait tool and attend 6 additional sessions with family members focused on personalized risk communication
- Attend regular checkups to measure weight and HbA1c at 6 and 12 months
- Have session attendance tracked throughout the program
- Family members of participants may also be asked to complete health assessments to measure any changes in their own health behaviors
Detailed description
Type 2 diabetes affects 38.4 million U.S. adults, and an additional 97.6 million adults have prediabetes and are at risk of developing the disease. This burden falls disproportionately on racial and ethnic minority families and rural communities.
This clinical trial aims to determine whether embedding family engagement and family health history into the Diabetes Prevention Program (DPP) improves adherence, weight loss, and glycemic outcomes among adults with prediabetes, compared to the standard individual-focused DPP.
Participants will be 200 index participants with prediabetes, along with their family members, recruited from rural and urban sites and stratified by geographic location. Index participants will be block randomized to receive either standard DPP or an adapted version that adds 6 weeks of family health history and genetics education-using the CDC's My Family Health Portrait tool-paired with family participation and skill-building sessions.
All participants will attend regular clinic visits to monitor weight and HbA1c at 6 and 12 months and will have session attendance tracked throughout. Family members will also complete health assessments to measure whether health improvements extend beyond the index participant, and researchers will use the Actor-Partner Interdependence Model to identify factors explaining variation in family-level outcomes.
This is a 2-arm randomized controlled trial comparing standard DPP to a family-adapted DPP incorporating family health history, genetics education, and family skill-building.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lifestyle Engagement through Genetics and Collaborative familY DPP (LEGACY DPP) | Experimental | Behavioral: LEGACY DPPParticipants will receive the LEGACY DPP intervention |
| Diabetes Prevention Program (DPP) | Active comparator | Behavioral: DPPParticipants will receive the DPP intervention |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥18 years.
- Fasting HbA1c 5.7-6.4% confirmed by CLIA-waived point-of-care testing.
- Body Mass Index ≥25 kg/m².
- Able to provide informed consent.
- Has an adult household/family or framily (fictive kin) member willing to enroll as a paired participant.
Key exclusion criteria (7 listed)
- Minors <18 years
- Prior diagnosis of Type 1 or Type 2 Diabetes.
- HbA1c ≥6.5% at screening (Aim 1/2 curriculum eligibility)
- Current glucose-lowering medication use
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LEGACY DPPThe index partner will participate in an adapted DPP as a dyad with a family member with family health history and family participation and skill building Participants will receive * family health history sessions * core behavioral weight loss group sessions * a family skill building segment covering cohesion and communication during core sessions | Behavioural | Lifestyle Engagement through Genetics and Collaborative familY DPP (LEGACY DPP) |
| DPPThe index partner will participate in standard DPP Participants will receive - core behavioral weight loss group sessions | Behavioural | Diabetes Prevention Program (DPP) |
Primary outcome
Mean Percent change in body weight
Time frame: Baseline, 6 months, 12 months
Body weight (kg) expressed as a continuous variable will be collected on a digital scale.
15 secondary outcomes
Mean Change in Blood Pressure ( Systolic and diastolic)
Time frame: Baseline, 6 months, 12 months
Mean Change in glycosloated hemoglobin(HbA1c)(fasting, CLIA-waived assay)
Time frame: Baseline, 6 months, 12 months
Mean Change in Fasting lipid panel (total cholesterol, High Denisity Lipids(HDL), Low density lipids (LDL), triglycerides)
Time frame: Baseline, 6 months, 12 months
Mean Change in Skin carotenoids
Time frame: Baseline, 6 months, 12 months
Mean Change in Physical activity steps
Time frame: Baseline, 6 months, 12 months
Mean Change in Self-Regulation of Eating Behaviors
Time frame: Baseline, 6 months, 12 months
Mean Change in Self-Efficacy of Eating Behaviors
Time frame: Baseline, 6 months, 12 months
Mean Change in Self-Efficacy of Physical Activity
Time frame: Baseline, 6 months, 12 months
Mean Change in Social Support for Eating
Time frame: Baseline, 6 months, 12 months
Mean Change in Social Support for Exercise
Time frame: Baseline, 6 months, 12 months
Mean Change in Family Communication
Time frame: Baseline, 6 months, 12 months
Mean Change in Family Cohesion
Time frame: Baseline, 6 months, 12 months
Mean Change in Family Emotional Involvement
Time frame: Baseline, 6 months, 12 months
Mean Change in Family Perceived Criticism
Time frame: Baseline, 6 months, 12 months
Mean Change in Family Collaborative problem solving
Time frame: Baseline, 6 months, 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
Related trials for Prediabetes
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
RecruitingObservational study
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Overweight, Prediabetic State
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Recruiting
CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes
PreDiabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Candice L Alick, PhD principal investigator
Morehouse School of Medicine
Tennille Leak-Johnson, PhD principal investigator
Morehouse School of Medicine
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing LEGACY DPP and DPP in people with Prediabetes and Weight Loss, run by Morehouse School of Medicine.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Candice L Alick, PhD (404-752-1009, calick@msm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Percent change in body weight (time frame: Baseline, 6 months, 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.